<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061425</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hLL2-06-EU</org_study_id>
    <nct_id>NCT00061425</nct_id>
  </id_info>
  <brief_title>Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG</brief_title>
  <official_title>Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized&#xD;
      (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma&#xD;
      (NHL) at different dose levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radiolabeled epratuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one&#xD;
             regimen of standard chemotherapy. (All histological grades of NHL will be eligible for&#xD;
             this trial.)&#xD;
&#xD;
          -  Measureable via CT, with at least one lesion &gt; or = 1.5cm in one or both dimensions.&#xD;
             (Splenic tumors in absence of other tumors will not qualify.)&#xD;
&#xD;
          -  Radiological studies (ie - CT) must be performed within 4 weeks prior to study start.&#xD;
&#xD;
          -  Acceptable tumor burden that will allow adequate follow-up and evaluation.&#xD;
&#xD;
          -  Less that 25% bone marrow involvement, determined by bone marrow biopsy.&#xD;
&#xD;
          -  Must observe the following washout periods:&#xD;
&#xD;
        At least 4 weeks beyond any major surgery. At least 4 weeks beyond any radiation therapy to&#xD;
        the index lesion, and has recovered from radiation-induced toxicity.&#xD;
&#xD;
        At least 4 weeks beyond chemotherapy and/or immunotherapy. At least 2 weeks beyond&#xD;
        corticosteriod(s) use and blood counts are with laboratory criteria.&#xD;
&#xD;
          -  Must have Karnofsky score &gt;70% (or equivalent, ECOG 0-2) with expected survival of at&#xD;
             least 6 months.&#xD;
&#xD;
          -  Serum creatinine &lt; or = 1.5mg/dl or creatinine clearance &gt; or = 50ml/min.&#xD;
&#xD;
          -  Serum bilirubin &lt; or = 2mg/dl.&#xD;
&#xD;
          -  Hemoglobin &gt; or = 10 g/dl; WBC &gt; or = 3000/mm3; granulocyte count &gt; or = 150/mm3;&#xD;
             platelet count &gt; or = 100,000/mm3 with out transfusions or cytokines for at least 30&#xD;
             days prior to study.&#xD;
&#xD;
          -  Immunomedics ELISA assay of HahLL2 &lt; 100ng/ml for those with prior history of&#xD;
             monoclonal antibody infusions.&#xD;
&#xD;
          -  Cognizant informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>May 27, 2003</study_first_submitted>
  <study_first_submitted_qc>May 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2003</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <keyword>NHL</keyword>
  <keyword>recurrent B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epratuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

